Share this post on:

The findings and conclusions in this short article are these on the authors and usually do not necessarily represent the views of the Centers for Disease Control and Prevention Author Contributions Conceived and created the experiments: RMS JRH ED NM-H. Performed the experiments: RMS AM-J MT TS JRH NM-H. Analyzed the information: RMS JRH. Contributed reagents/materials/analysis tools: MT ED NM-H. Wrote the paper: RMS JRH. Revision: JRH RMS. References 1. Casadevall A, Fantastic JR, editors Cryptococcus neoformans. Washington, DC: ASM Press. 542 p. two. Fantastic JR, Casadevall A The History of Cryptococcus and Cryptococcosis. In: Heitman J, Kozel TR, Kwon-Chung J, Excellent J, Casadevall A, editors. Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC: ASM Press. 1726. 3. Heitman J, Kozel TR, Kwon-Chung J, Best J, Casadevall A, editors Cryptococcus: from pathogen to model yeast. Washington, DC: ASM Press. 4. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, et al. A comparison of amphotericin B alone and combined with flucytosine within the therapy of cryptoccal meningitis. N Engl J Med 301: 126131. five. Butler WT, Alling DW, Spickard A, Utz JP Diagnostic and Prognostic Worth of Clinical and ASP015K custom synthesis Laboratory Findings in Cryptococcal Meningitis, a Followup Study of Forty Sufferers. N Engl J Med 270: 5967. six. Committee UKCHCSS, Garvey L, Winston A, Walsh J, Post F, et al. HIV-associated central nervous system illnesses within the recent mixture antiretroviral therapy era. Eur J Neurol 18: 527534. 7. Asselman V, Thienemann F, Pepper DJ, Boulle A, Wilkinson RJ, et al. 23148522 Central nervous program disorders immediately after beginning antiretroviral therapy in South Africa. AIDS 24: 28712876. 8. Wadhwa A, Kaur R, Bhalla P Profile of central nervous technique illness in HIV/AIDS sufferers with unique reference to cryptococcal infections. Neurologist 14: 247251. 9. Kwon-Chung KJ, Bennett JE Epidemiologic differences involving the two varieties of Cryptococcus neoformans. Am J Epidemiol 120: 123130. 10. Kwon-Chung KJ, Bennett JE High prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions. Zentralbl Bakteriol Mikrobiol Hyg A 257: 213218. 11. Speed B, Dunt D Clinical and host variations in between infections together with the two varieties of Cryptococcus neoformans. Clin Infect Dis 21: 2834; discussion 3526. 12. Lalloo D, Fisher D, Naraqi S, Laurenson I, Temu P, et al. Cryptococcal meningitis leading to blindness in previously healthful Melanesian adults in Papua New Guinea. Q J Med 87: 343349. 13. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, et al. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9: 189195. 14. Byrnes EJ, 3rd, Li W, Lewit Y, Perfect JR, Carter DA, et al. 1st reported case of Cryptococcus gattii inside the Southeastern USA: implications for HIV-RT inhibitor 1 chemical information travelassociated acquisition of an emerging pathogen. PLoS A single 4: e5851. 15. Lopez-Martinez R, Soto-Hernandez JL, Ostrosky-Zeichner L, CastanonOlivares LR, Angeles-Morales V, et al. Cryptococcus neoformans var. gattii amongst patients with cryptococcal meningitis in Mexico. Initially observations. Mycopathologia 134: 6164. 16. MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 13: 4250. 17. Fyfe M, MacDougall L, Romney M, Starr M, Pearce M, et al. Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus.The findings and conclusions within this article are those of your authors and usually do not necessarily represent the views with the Centers for Illness Control and Prevention Author Contributions Conceived and developed the experiments: RMS JRH ED NM-H. Performed the experiments: RMS AM-J MT TS JRH NM-H. Analyzed the information: RMS JRH. Contributed reagents/materials/analysis tools: MT ED NM-H. Wrote the paper: RMS JRH. Revision: JRH RMS. References 1. Casadevall A, Ideal JR, editors Cryptococcus neoformans. Washington, DC: ASM Press. 542 p. two. Perfect JR, Casadevall A The History of Cryptococcus and Cryptococcosis. In: Heitman J, Kozel TR, Kwon-Chung J, Best J, Casadevall A, editors. Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC: ASM Press. 1726. three. Heitman J, Kozel TR, Kwon-Chung J, Ideal J, Casadevall A, editors Cryptococcus: from pathogen to model yeast. Washington, DC: ASM Press. four. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, et al. A comparison of amphotericin B alone and combined with flucytosine inside the remedy of cryptoccal meningitis. N Engl J Med 301: 126131. 5. Butler WT, Alling DW, Spickard A, Utz JP Diagnostic and Prognostic Value of Clinical and Laboratory Findings in Cryptococcal Meningitis, a Followup Study of Forty Individuals. N Engl J Med 270: 5967. 6. Committee UKCHCSS, Garvey L, Winston A, Walsh J, Post F, et al. HIV-associated central nervous method illnesses within the current combination antiretroviral therapy era. Eur J Neurol 18: 527534. 7. Asselman V, Thienemann F, Pepper DJ, Boulle A, Wilkinson RJ, et al. 23148522 Central nervous system problems right after beginning antiretroviral therapy in South Africa. AIDS 24: 28712876. 8. Wadhwa A, Kaur R, Bhalla P Profile of central nervous program disease in HIV/AIDS individuals with special reference to cryptococcal infections. Neurologist 14: 247251. 9. Kwon-Chung KJ, Bennett JE Epidemiologic differences amongst the two varieties of Cryptococcus neoformans. Am J Epidemiol 120: 123130. ten. Kwon-Chung KJ, Bennett JE Higher prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions. Zentralbl Bakteriol Mikrobiol Hyg A 257: 213218. 11. Speed B, Dunt D Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 21: 2834; discussion 3526. 12. Lalloo D, Fisher D, Naraqi S, Laurenson I, Temu P, et al. Cryptococcal meningitis leading to blindness in previously wholesome Melanesian adults in Papua New Guinea. Q J Med 87: 343349. 13. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, et al. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9: 189195. 14. Byrnes EJ, 3rd, Li W, Lewit Y, Fantastic JR, Carter DA, et al. Initially reported case of Cryptococcus gattii inside the Southeastern USA: implications for travelassociated acquisition of an emerging pathogen. PLoS A single 4: e5851. 15. Lopez-Martinez R, Soto-Hernandez JL, Ostrosky-Zeichner L, CastanonOlivares LR, Angeles-Morales V, et al. Cryptococcus neoformans var. gattii amongst patients with cryptococcal meningitis in Mexico. First observations. Mycopathologia 134: 6164. 16. MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 13: 4250. 17. Fyfe M, MacDougall L, Romney M, Starr M, Pearce M, et al. Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus.

Share this post on:

Author: haoyuan2014